File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1182/blood-2012-05-431460
- Scopus: eid_2-s2.0-84867810745
- PMID: 22919026
- WOS: WOS:000311619300014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
Title | SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group |
---|---|
Authors | |
Keywords | Cancer prognosis Cancer recurrence Cancer regression Cancer risk Cancer staging |
Issue Date | 2012 |
Publisher | American Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/ |
Citation | Blood, 2012, v. 120 n. 15, p. 2973-2980 How to Cite? |
Abstract | Natural killer/T-cell lymphoma is rare and aggressive, with poor outcome. Optimal treatment remains unclear. A novel regimen dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) showed promise in phase 1/2 studies with restrictive recruitment criteria. To define the general applicability of SMILE, 43 newly diagnosed and 44 relapsed/refractory patients (nasal, N = 60, nonnasal, N = 21; disseminated, N = 6; male, N = 59; female, N = 28) at a median age of 51 years (23-83 years) were treated. Poor-risk factors included stage III/IV disease (56%), international prognostic index of 3 to 5 (43%), and Korean prognostic scores of 3 to 4 (41%). A median of 3 (0-6; total = 315) courses of SMILE were administered. Significant toxicities included grade 3/4 neutropenia (N = 57; 5 sepsis-related deaths); grade 3/4 thrombocytopenia (N = 36); and nephrotoxicity (N = 15; 1 acute renal failure and death). Interim analysis after 2 to 3 cycles showed complete remission rate of 56%, partial remission rate of 22%, giving an overall response rate of 78%. On treatment completion, the overall-response rate became 81% (complete remission = 66%, partial remission = 15%). Response rates were similar for newly diagnosed or relapsed/refractory patients. At a median follow-up of 31 months (1-84 months), the 5-year overall survival was 50% and 4-year disease-free-survival was 64%. Multivariate analysis showed that international prognostic index was the most significant factor impacting on outcome and survivals. |
Persistent Identifier | http://hdl.handle.net/10722/164336 |
ISSN | 2023 Impact Factor: 21.0 2023 SCImago Journal Rankings: 5.272 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, YL | en_US |
dc.contributor.author | Kim, WS | en_US |
dc.contributor.author | Lim, ST | en_US |
dc.contributor.author | Kim, SJ | en_US |
dc.contributor.author | Tang, T | en_US |
dc.contributor.author | Tse, EWC | en_US |
dc.contributor.author | Leung, AYH | en_US |
dc.contributor.author | Chim, JCS | en_US |
dc.date.accessioned | 2012-09-20T07:58:01Z | - |
dc.date.available | 2012-09-20T07:58:01Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Blood, 2012, v. 120 n. 15, p. 2973-2980 | en_US |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | http://hdl.handle.net/10722/164336 | - |
dc.description.abstract | Natural killer/T-cell lymphoma is rare and aggressive, with poor outcome. Optimal treatment remains unclear. A novel regimen dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) showed promise in phase 1/2 studies with restrictive recruitment criteria. To define the general applicability of SMILE, 43 newly diagnosed and 44 relapsed/refractory patients (nasal, N = 60, nonnasal, N = 21; disseminated, N = 6; male, N = 59; female, N = 28) at a median age of 51 years (23-83 years) were treated. Poor-risk factors included stage III/IV disease (56%), international prognostic index of 3 to 5 (43%), and Korean prognostic scores of 3 to 4 (41%). A median of 3 (0-6; total = 315) courses of SMILE were administered. Significant toxicities included grade 3/4 neutropenia (N = 57; 5 sepsis-related deaths); grade 3/4 thrombocytopenia (N = 36); and nephrotoxicity (N = 15; 1 acute renal failure and death). Interim analysis after 2 to 3 cycles showed complete remission rate of 56%, partial remission rate of 22%, giving an overall response rate of 78%. On treatment completion, the overall-response rate became 81% (complete remission = 66%, partial remission = 15%). Response rates were similar for newly diagnosed or relapsed/refractory patients. At a median follow-up of 31 months (1-84 months), the 5-year overall survival was 50% and 4-year disease-free-survival was 64%. Multivariate analysis showed that international prognostic index was the most significant factor impacting on outcome and survivals. | - |
dc.language | eng | en_US |
dc.publisher | American Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/ | - |
dc.relation.ispartof | Blood | en_US |
dc.rights | This research was originally published in The Hematologist: ASH News and Reports. Author(s). Title. The Hematologist: ASH News and Reports. Year;Vol,Issue:pp-pp. © the American Society of Hematology. | - |
dc.subject | Cancer prognosis | - |
dc.subject | Cancer recurrence | - |
dc.subject | Cancer regression | - |
dc.subject | Cancer risk | - |
dc.subject | Cancer staging | - |
dc.title | SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group | en_US |
dc.type | Article | en_US |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | en_US |
dc.identifier.email | Tse, EWC: ewctse@hku.hk | en_US |
dc.identifier.email | Leung, AYH: ayhleung@hku.hk | en_US |
dc.identifier.email | Chim, JCS: jcschim@hku.hk | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.identifier.authority | Tse, EWC=rp00471 | en_US |
dc.identifier.authority | Leung, AYH=rp00265 | en_US |
dc.identifier.authority | Chim, JCS=rp00408 | en_US |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1182/blood-2012-05-431460 | - |
dc.identifier.pmid | 22919026 | - |
dc.identifier.scopus | eid_2-s2.0-84867810745 | - |
dc.identifier.hkuros | 209903 | en_US |
dc.identifier.volume | 120 | - |
dc.identifier.issue | 15 | - |
dc.identifier.spage | 2973 | en_US |
dc.identifier.epage | 2980 | en_US |
dc.identifier.isi | WOS:000311619300014 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0006-4971 | - |